(Q38153446)

29 August 2017

Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives (English)

1 reference

29 August 2017

7

1 reference

29 August 2017

8

1 reference

29 August 2017

10

1 reference

29 August 2017

11

1 reference

29 August 2017

12

1 reference

29 August 2017

Massimo Di Maio

3

0 references

Maria Carmela Piccirillo

series ordinal

4

object named as

Maria Carmela Piccirillo

1 reference

29 August 2017

1

Raffaele Costanzo

1 reference

29 August 2017

2

Agnese Montanino

1 reference

29 August 2017

5

Claudia Sandomenico

1 reference

29 August 2017

Pasqualina Giordano

6

1 reference

PubMed ID

24134422

29 August 2017

Francesco Perrone

series ordinal

9

1 reference

29 August 2017

1 October 2013

1 reference

Expert Review of Anticancer Therapy

29 August 2017

1 reference

29 August 2017

13

1 reference

29 August 2017

10

1 reference

29 August 2017

1207-1218

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

29 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Gefitinib in non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2013.845092

10.1586/14737140.2013.845092

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

24134422